Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3474587 | 0.91 | RXRA (0.55) | RXRANR1H2NR1H3MAPTSMN1; SMN2 | |
| SCHEMBL3471277 | 0.91 | MAPT (0.57) | RXRANR1H2NR1H3MAPTSMN1; SMN2 | |
| SCHEMBL3471324 | 0.91 | MAPT (0.59) | RXRANR1H2NR1H3MAPTSMN1; SMN2 | |
| SCHEMBL3473163 | 0.91 | MAPT (0.62) | RXRANR1H2NR1H3MAPTSMN1; SMN2 | |
| SCHEMBL3472362 | 0.91 | RXRA (0.54) | RXRANR1H2NR1H3MAPTSMN1; SMN2 | |
| SCHEMBL3473316 | 0.90 | RXRA (0.53) | RXRANR1H2NR1H3MAPTSMN1; SMN2 | |
| SCHEMBL3474844 | 0.90 | RXRA (0.55) | RXRANR1H2NR1H3MAPTSMN1; SMN2 | |
| SCHEMBL3472273 | 0.90 | MAPT (0.56) | RXRANR1H2NR1H3MAPTSMN1; SMN2 | |
| SCHEMBL14624228 | 0.90 | RXRA (0.53) | RXRANR1H2NR1H3MAPTSMN1; SMN2 | |
| SCHEMBL3471973 | 0.90 | RXRA (0.55) | RXRANR1H2NR1H3MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| CN-101248048-B | Imidazole based LXR modulators | EXELIXIS INC | 2013-08-28 | — | — | CN | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| CN-101248048-A | Imidazole based LXR modulators | EXELIXIS INC (US) | 2008-08-20 | — | — | CN | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | RXRA 18/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.